Previous 10 | Next 10 |
Autolus Therapeutics (AUTL) has priced its public offering of ~14.3M ADSs at $7.00/ADS, for total gross proceeds of ~$100M. Each ADS representing one ordinary share.Underwriters' over-allotment is an additional ~2.1M ADSs.Closing date is February 12.Shares down 1.3% premarket.P...
Autolus Therapeutics (AUTL) commences an underwritten public offering of up to $100M ADSs.Each ADS representing one ordinary share.Underwriters' option to purchase up to an additional $15M of ADSs.Actual size or terms of the offering are yet to be finalised.Press Release For further de...
LONDON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2020 financial results and operati...
Autolus Therapeutics (AUTL) updates its business outlook, strengthening its focus CAR T cell therapy candidate, AUTO1, which is being investigated in relapsed/refractory adult B-Acute Lymphoblastic Leukemia ((ALL)). The company is prioritizing this program with data expected in 2022 and plans...
• Company prioritizes AUTO1, a potentially transformational treatment for Adult Acute Lymphoblastic Leukemia (ALL), with full data from the AUTO1-AL1 study expected in 2022 • Company intends to partner AUTO3, ahead of progressing into the next phase of development ...
LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in investor conferences through January 2021. ...
Thinly traded Autolus Therapeutics ([[AUTL]] +11.6%) has announced new data from Phase 1/2 study, ALEXANDER, evaluating company's CD19 and CD22 dual targeting CAR T candidate, AUTO3 in relapsed/refractory diffuse large B cell lymphoma ((DLBCL)). Data were presented at the American Societ...
AUTO3 continues to show a differentiated product profile supporting outpatient administration Conference call and webcast to be held Monday , December 7 , 2020 at 4 :00 p m ET / 9 :00 pm ...
Updated data from the ALLCAR study suggests AUTO1’s potential for transformational activity in adult patients with r/r ALL Conference call and webcast to be held Monday, December 7, 2020 at 4:00 pm ET / 9:00 pm GMT LONDON, Dec. 05, 2020 (GLOBE NEWSWIRE) -- A...
Autolus Therapeutics ([[AUTL]] +8.5%) announces publication of data from Phase 1 study evaluating AUTO6 (1RG-CAR T) in childhood neuroblastoma, in Science Translational Medicine. The trial was sponsored and run by Cancer Research UK’s Centre for Drug Development.New results h...
News, Short Squeeze, Breakout and More Instantly...
Autolus Therapeutics plc Company Name:
AUTL Stock Symbol:
NASDAQ Market:
Autolus Therapeutics plc Website:
LONDON, July 26, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2024 financial results and operational highlights befo...
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated wi...